Clinical Trial Design, Precision Medicine Added To CDRH Science Priorities

21 Sep 2016
News

Executive Summary

US FDA's device center issued its third annual regulatory science priorities list, adding emphasis on clinical trial designs, and precision medicine and biomarkers, while dropping human-factors engineering from the list.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

United States

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Policy & Regulation Innovation Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT103858

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT103858

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Clinical Trial Design, Precision Medicine Added To CDRH Science Priorities

News

Executive Summary

Related Content

FDA Details When Human Factors Testing Is A Must

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert